BEFORE THE FINANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: FRIDAY, DECEMBER 3, 2010

10 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 88868

INDEX

ITEM DESCRIPTION	PAGE	NO.
1. CALL TO ORDER.		3
2. ROLL CALL.		3
3. CONSIDERATION OF RISK PREMIUM OPTIONS FOR LOAN PROGRAMS, INCLUDING AMENDMENTS TO WARRANT COVERAGE REQUIREMENTS IN LOAN ADMINISTRATION POLICY AND ADOPTION OF INTERIM REGULATIONS TO OFFER PAYBACK OF MULTIPLE OF LOAN AMOUNT AS ALTERNATIVE TO WARRANT COVERAGE.		6
4. DISCUSSION REGARDING BOND MARKET AND FUTURE IMPLICATIONS FOR CIRM.		29
5. PUBLIC COMMENT.	NO	NE
6. ADJOURNMENT.		33

	BARRISTERS' REPORTING SERVICE
1	FRIDAY, DECEMBER 3, 2010
2	10 A.M.
3	
4	MS. KING: I WILL THEN TAKE A FORMAL ROLL
5	CALL WHICH I CAN AUGMENT AS OTHERS JOIN.
6	ROBERT PRICE FOR ROBERT BIRGENEAU. FLOYD
7	BLOOM. MARCY FEIT. MICHAEL GOLDBERG.
8	MR. GOLDBERG: HERE.
9	MS. KING: BOB KLEIN.
10	CHAIRMAN KLEIN: HERE.
11	MS. KING: TED LOVE.
12	DR. LOVE: HERE.
13	MS. KING: ED PENHOET. PHIL PIZZO.
14	DR. PIZZO: HERE.
15	MS. KING: DUANE ROTH.
16	MR. ROTH: HERE.
17	MS. KING: DAVID SERRANO-SEWELL. JEFF
18	SHEEHY.
19	MR. SHEEHY: HERE.
20	MS. KING: OSWALD STEWARD. AND ART
21	TORRES.
22	WE DO NEED THREE MEMBERS TO JOIN US IN
23	ORDER FOR US TO HAVE A QUORUM.
24	CHAIRMAN GOLDBERG: MELISSA, CAN WE ALSO
25	POLL TO UNDERSTAND WHERE WE HAVE MEMBERS OF THE
	3
	-

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PUBLIC IN ATTENDANCE?
2	MS. KING: SURE. AND I WILL START HERE IN
3	SAN FRANCISCO. WE DO HAVE MEMBERS OF THE PUBLIC
4	HERE WITH US AT THE CIRM. DO YOU HAVE MEMBERS OF
5	PUBLIC AT STANFORD?
6	CHAIRMAN GOLDBERG: NO, WE DON'T. CAN WE
7	INTRODUCE THE MEMBERS OF THE PUBLIC. DO WE HAVE ANY
8	REPRESENTATIVES OF THE INDUSTRY IN SAN FRANCISCO?
9	MS. KING: WE DO. AND IF THEY WOULD LIKE
10	TO INTRODUCE THEMSELVES, WE CAN ASK THEM TO DO THAT.
11	IF THE MEMBERS OF THE PUBLIC THAT ARE HERE ARE
12	WILLING TO INTRODUCE THEMSELVES BY NAME, WOULD YOU
13	PLEASE COME TO THE MICROPHONE IF YOU WOULDN'T MIND.
14	WHO JUST JOINED?
15	MR. SERRANO-SEWELL: DAVID.
16	MS. KING: THANK YOU SO MUCH, DAVID. AND
17	JUST A QUICK CHECK. DO YOU HAVE ANY MEMBERS OF THE
18	PUBLIC THERE WITH YOU AT SAN FRANCISCO AIRPORT?
19	MR. SERRANO-SEWELL: NO.
20	MS. KING: OKAY. VERY GOOD. THANK YOU.
21	IF THE MEMBERS OF THE PUBLIC HERE IN SAN FRAN WOULD
22	LIKE TO INTRODUCE YOURSELVES, WE INVITE YOU TO DO SO
23	AT THIS TIME. THANK YOU.
24	MR. PLUNKETT: MATTHEW PLUNKETT, IPERIAN.
25	MR. REED: DON REED, PUBLIC.
	4
	•

1	MS. KING: OKAY. AND THERE ARE NONE AT
2	STANFORD; IS THAT CORRECT?
3	CHAIRMAN GOLDBERG: NO, THERE IS NOT.
4	DR. PIZZO: THERE'S NO MEMBERS OF THE
5	PUBLIC HERE.
6	MS. KING: OKAY. AND THERE ARE NONE AT
7	SAN FRANCISCO AIRPORT. WE DON'T HAVE A MEMBER AT
8	KLEIN FINANCIAL, BUT IT WAS A NOTICED LOCATION. SO
9	IF THERE ARE MEMBERS OF THE PUBLIC, THEY WOULD BE ON
10	THE LINE. ANY MEMBERS OF THE PUBLIC AT KLEIN
11	FINANCIAL? HEARING NONE, I'LL MOVE ON.
12	WHO JUST JOINED?
13	DR. PRICE: BOB PRICE.
14	MS. KING: THANK YOU SO MUCH, DR. PRICE.
15	AND QUICK QUESTION. DO YOU HAVE ANY MEMBERS OF THE
16	PUBLIC WITH YOU THERE AT UCLA?
17	DR. PRICE: I DO NOT.
18	MS. KING: OKAY. DR. STEWARD IS NOT YET
19	WITH US, SO WE'LL CHECK BACK ON IRVINE. DUANE ROTH,
20	DO YOU HAVE MEMBERS OF THE PUBLIC AT CONNECT?
21	MR. ROTH: NO.
22	MS. KING: DR. PENHOET IS NOT YET ON THE
23	LINE. WE'LL COME BACK TO HIM. AND DR. LOVE AT ONYX
24	PHARMACEUTICALS, DO YOU HAVE MEMBERS OF THE PUBLIC
25	WITH YOU?
	ς

1	DR. LOVE: NO.
2	MS. KING: OKAY. VERY GOOD. THANK YOU.
3	CHAIR GOLDBERG, IF YOU WOULD LIKE TO PROCEED.
4	CHAIRMAN GOLDBERG: YEAH. SO THE PURPOSE
5	OF THIS MEETING IS TO FOCUS ON AGENDA ITEM NO. 3
6	PRINCIPALLY. WE NEED TO ESTABLISH A SENSE OF THE
7	COMMITTEE FOR RECOMMENDATION TO THE ICOC AND PERHAPS
8	A MOTION, IF WE HAVE A QUORUM, CONCERNING THE RISK
9	PREMIUM OPTION FOR LOAN PROGRAMS, THE AMENDMENTS TO
10	THE WARRANT COVERAGE, AND THE DISCUSSION OF INTERIM
11	REGULATIONS ON A PAYBACK MULTIPLE OF THE LOAN
12	ALTERNATIVE.
13	MS. KING: WHO JUST JOINED?
14	MR. TORRES: ART.
15	MS. KING: GREAT. THANK YOU SO MUCH, ART.
16	CHAIRMAN GOLDBERG: AND IF WE HAVE TIME,
17	WE CAN DISCUSS NO. 4, THE ENVIRONMENT FOR BOND
18	FINANCING IN THE STATE OF CALIFORNIA, BUT THAT WILL
19	BE DISCRETIONARY ONLY IF TIME ALLOWS.
20	MS. KING: MR. GOLDBERG, JUST SO YOU KNOW,
21	WE DO NOW HAVE A QUORUM.
22	CHAIRMAN GOLDBERG: THANK YOU. SO, DUANE,
23	WOULD YOU LIKE TO DISCUSS THE PROPOSED AMENDMENTS
24	FOR THE COMPANY AND PRODUCT-BACKED LOANS, OR WOULD
25	YOU LIKE STAFF TO DO THAT ON BEHALF OF THE LOAN TASK

1	FORCE?
2	MR. ROTH: SO WHY DON'T I ASK EITHER JAMES
3	OR ELONA TO START IT OFF, AND THEN I'M MAKE SOME
4	COMMENTS.
5	MR. HARRISON: I CAN DO THAT, MICHAEL.
6	CHAIRMAN GOLDBERG: GREAT. AND, JAMES, I
7	THINK, GIVEN THE BACKGROUND, WE CAN FOCUS JUST ON
8	THE PROPOSED AMENDMENTS RATHER THAN THE CURRENT
9	STATUS OF THE LANGUAGE.
10	MR. HARRISON: SURE. I'D BE HAPPY TO. SO
11	ADHERING TO MICHAEL'S DIRECTION, THE PROPOSAL TO
12	MODIFY THE WARRANT COVERAGE ADDRESS BOTH
13	COMPANY-BACKED LOANS AS WELL AS THE PRODUCT-BACKED
14	LOANS. FOR COMPANY-BACKED LOANS, CURRENTLY WE HAVE
15	A REQUIREMENT WHERE THE LOAN RECIPIENT IS REQUIRED
16	TO PROVIDE WARRANT COVERAGE EQUAL TO 25 PERCENT OF
17	THE LOAN AMOUNT IF THE LOAN RECIPIENT HAS MET TWO
18	CRITERIA, ONE OF WHICH IS THAT THE LOAN RECIPIENT
19	HAS RAISED THREE TIMES THE AMOUNT OF THE LOAN IN
20	PRIOR FINANCINGS. AND THE SECOND IS THAT THE LOAN
21	RECIPIENT HAS AN AGREEMENT WITH A BIOTECH OR PHRMA
22	COMPANY WHICH PROVIDES FOR THE PAYMENT OF LICENSING
23	FEES OR MILESTONE PAYMENTS.
24	WHAT WE WOULD PROPOSE TO DO IS TO CHANGE
25	THE "AND" TO THE "OR." IN OTHER WORDS, THE LOAN

1	RECIPIENT WOULD BE REQUIRED TO PROVIDE COVERAGE AT
2	THE RATE OF 25 PERCENT OF THE LOAN AMOUNT IF THE
3	LOAN RECIPIENT MEETS EITHER ONE OF THOSE TWO
4	CRITERIA. AND THEN THAT CHANGE WOULD BE
5	COMPLEMENTED BY CHANGING THE NEXT COVERAGE PORTION
6	TO SPECIFY THAT IF THE LOAN RECIPIENT HAS ONLY MET
7	ONE OF THOSE CRITERIA OR EXCUSE ME IF THE LOAN
8	RECIPIENT HAS NOT MET EITHER OF THOSE CRITERIA, THAT
9	THEY WOULD BE REQUIRED TO PROVIDE WARRANT COVERAGE
10	EQUAL TO 50 PERCENT OF THE LOAN AMOUNT.
11	WITH RESPECT TO THE PRODUCT-BACKED LOAN,
12	THE WARRANT COVERAGE WOULD DEPEND UPON THE
13	PERCENTAGE OF CIRM'S FUNDS COMPARED TO THE LOAN
14	RECIPIENT'S FUNDS FOR THE PROJECT FOR THE PERIOD
15	COVERED BY THE CIRM DISBURSEMENT. IN OTHER WORDS,
16	IF DURING THE PERIOD COVERED BY THE CIRM
17	DISBURSEMENT, CIRM'S FUNDS WERE EQUAL TO 60 PERCENT
18	OF WHAT WAS REQUIRED TO COMPLETE THE ACTIVITIES
19	SPECIFIED, THEN THE LOAN RECIPIENT WOULD BE REQUIRED
20	TO PROVIDE WARRANT COVERAGE EQUAL TO 60 PERCENT OF
21	THAT DISBURSEMENT. IF AT THE NEXT TRANCHE CIRM WAS
22	PUTTING IN 30 PERCENT AND THE LOAN RECIPIENT WAS
23	PUTTING IN 70 PERCENT, THEN CIRM EXCUSE ME
24	THEN THE LOAN RECIPIENT WOULD ONLY HAVE TO PROVIDE
25	warrant coverage equal to 30 percent of the

1	DISBURSEMENT.
2	SO THAT'S A VERY BRIEF SUMMARY.
3	CHAIRMAN GOLDBERG: THANK YOU, JAMES.
4	MR. ROTH: SO, MICHAEL, IT'S DUANE. JUST
5	SOME EDITORIAL COMMENT ON THIS. I FOUND THIS IDEA
6	TO BE VERY COMPELLING BECAUSE WE'RE SHARING THE RISK
7	IN A CERTAIN PERIOD OF TIME. AND BASED ON THE
8	CONTRIBUTION THAT EACH OF US PUTS IN, IT WOULD
9	DETERMINE THE WARRANT COVERAGE. SO IN A BRAND NEW
10	START-UP FIRST PRODUCT AND WE ARE VIRTUALLY A
11	HUNDRED PERCENT OF THE FUNDING, WE'D GET A HUNDRED
12	PERCENT WARRANT COVERAGE. IF IT'S A MORE MATURE
13	COMPANY AND THEY'RE ASKING US FOR A PORTION OF THE
14	FUNDING, THEN THAT PROPORTIONALITY WOULD DETERMINE
15	THE AMOUNT OF WARRANTS.
16	SO PREVIOUSLY THE LOWEST WE WOULD GO IS 50
17	PERCENT WARRANT COVERAGE. THIS WOULD ENABLE US THEN
18	TO GO DOWN. IF THE COMPANY IS PUTTING IN 70 PERCENT
19	OF THE MONEY AND WE'RE PITTING IN 30, THEN WE WOULD
20	GET 30 PERCENT WARRANT COVERAGE.
21	AND JUST ONE FINAL COMMENT, THAT THE WAY
22	THIS WOULD WORK IS THAT EACH TRANCHE OF THE MONEY
23	WOULD BE RESET ON THE BASIS OF THESE CRITERIA. SO
24	THE FIRST TRANCHE, IF IT WAS 50-50, WE'D GET 50
25	PERCENT WARRANT COVERAGE. IF THE AMOUNT OF MONEY
	g

1	THE COMPANY KICKED IN INCREASED, AND THEY WOULD
2	JUSTIFY THAT SO THAT WE'RE NOW 40, THE NEXT TRANCHE
3	WOULD THEN BE 40 PERCENT WARRANT COVERAGE FOR THAT
4	TRANCHE AND SO ON. SO IT WOULD TRACK WITH THE
5	ACTUAL COST INVESTMENT THAT THE COMPANY MAKES; AND,
6	OF COURSE, OUR AMOUNT IS FIXED.
7	DR. LOVE: SO, DUANE, I AGREE WITH YOUR
8	COMMENT. I GUESS I COULD HAVE ONE QUESTION THOUGH,
9	AND THAT IS BASED ON THE FEEDBACK THAT WE'VE BEEN
10	HEARING FROM COMPANIES. DO WE THINK THIS
11	MEANINGFULLY ADDRESSES THEIR CONCERNS?
12	MR. ROTH: YOU KNOW, TED, THE ONLY WAY TO
13	FIND OUT IS AT SOME POINT WE'VE GOT TO STICK TO WHAT
14	OUR PROGRAM WAS. OUR PROGRAM WAS CERTAINLY THERE
15	BEFORE THE RFP WENT OUT. AND SO I'M SURPRISED IF
16	COMPANIES, YOU KNOW, WENT THROUGH THE PROCESS AND
17	THEN WERE AWARDED THE GRANT AND THEN SUDDENLY SAY,
18	WELL, THEY WANT TO CHANGE THAT. I THINK THAT WHAT
19	I'VE LEARNED SO FAR FROM THE DISCUSSION WITH
20	COMPANIES IS THAT PROPORTIONALITY MAKES SENSE, AND
21	THE 50 PERCENT IS PROBABLY, IF THEY'RE PUTTING
22	IN IN THE TIME PERIOD, IF THEY'RE PUTTING IN MORE
23	THAN HALF THE MONEY, THEN THERE SHOULD BE A LOWER
24	THRESHOLD.
25	BUT THE ANSWER, TED, IS I DON'T THINK YOU
	10

1	KNOW UNTIL YOU ACTUALLY PUT IT OUT THERE. AND IF IT
2	BECOMES AN ISSUE, THEN CERTAINLY WE CAN LOOK AT
3	OTHER ALTERNATIVES TO THAT. BUT I BELIEVE IT'S
4	INHERENTLY FAIR BASED ON EVERYTHING I'VE DONE IN
5	TERMS OF DRUG DEVELOPMENT ON THIS SUBJECT ABOUT THE
6	WARRANT COVERAGE THAT WE'RE PROPOSING EVEN IN THE
7	CURRENT PLAN IS VERY MUCH JUSTIFIED. IT'S LIKE A
8	BRIDGE LOAN. IT'S EVEN BETTER THAN A BRIDGE LOAN
9	BECAUSE IN THE BRIDGE LOAN, THE COMPANY HAS TO
10	BASICALLY PUT THEM IN THE FIRST SECURED POSITION.
11	YOU GOT TO REPAY THE MONEY AND THEY'RE GETTING AT
12	LEAST 50 PERCENT WARRANT COVERAGE.
13	IN OUR CASE YOU'RE ON A PRODUCT LOAN.
14	IT'S NOT A COMPANY LOAN. THOSE BRIDGE LOANS ARE ALL
15	COMPANY. SO TO ME THAT'S THE BEST CRITERIA TO LOOK
16	AT AND SAY WE ARE FAR, FAR MORE GENEROUS THAN BRIDGE
17	LOANS. AND WE'RE ASKING FOR THE SAME AMOUNT OF
18	COVERAGE.
19	DR. LOVE: FAIR ENOUGH.
20	MR. ROTH: ONE THING I WOULD SAY AND THEN
21	I'LL BE QUIET, BUT IF WE ADOPT THIS, I WOULD SUGGEST
22	THAT WE ADOPT IT AND BE RETROSPECTIVE. SO IF THERE
23	IS A CHANGE THAT'S MADE, WE'D ADJUST THE WARRANTS
24	BASED ON THAT CHANGE IF THE BOARD FINALLY AGREES TO
25	IT, BUT FOR NOW I WOULD STAY WITH THE FIRST TRANCHE

1	ANYWAY IS AT 50 PERCENT.
2	CHAIRMAN KLEIN: SO, DUANE, THIS IS BOB
3	KLEIN. I SUPPORT THIS PROGRAM, AND I THINK IT'S GOT
4	A LOT OF LOGIC BEHIND IT. WE ALREADY HAVE A
5	PROVISION, I BELIEVE, IN OUR LOAN ADMINISTRATION
6	POLICY THAT SAYS THAT IF THERE ARE MORE FAVORABLE
7	TERMS THAT ARE ADOPTED, THAT A COMPANY CAN ELECT TO
8	HAVE THOSE APPLIED TO THEM RATHER THAN THE CURRENT
9	TERMS THAT THEY ARE UNDER. IS THAT CORRECT, JAMES
10	HARRISON?
11	MR. HARRISON: WHAT THE LOAN
12	ADMINISTRATION POLICY SPECIFIES IS THAT IF
13	AMENDMENTS ARE MADE, THE LOAN RECIPIENT AND CIRM BY
14	CONTRACT MAY AGREE TO APPLY THEM TO THE LOAN
15	RECIPIENT.
16	MS. BAUM: MY UNDERSTANDING IS THAT THAT
17	LANGUAGE IS STILL UP AT THE OFFICE OF ADMINISTRATIVE
18	LAW, WHICH I THINK WILL BECOME PROMULGATED IN 30
19	DAYS OR SO.
20	DR. PIZZO: CAN I JUST ASK FOR ONE
21	CLARIFICATION?
22	CHAIRMAN GOLDBERG: DR. PIZZO, GO AHEAD.
23	DR. PIZZO: SO THIS IS TO BOB, I THINK,
24	WHICH IS SO DOES THAT APPLY, THE RETROACTIVITY,
25	APPLY ANYWHERE IN THE LIFE OF THE PROJECT, OR DO YOU

1	AMORTIZE IT TO WHERE YOU ARE IN THE LIFE OF THE
2	PROJECT?
3	CHAIRMAN KLEIN: SO WAS EVERYONE ABLE TO
4	HEAR DR. PIZZO'S QUESTION? DR. PIZZO ASKED THE
5	MICROPHONE IS OVER HERE, SO I'M NOT SURE. DOCTOR,
6	WOULD YOU REPEAT YOUR QUESTION?
7	DR. PIZZO: LET ME COME TO A DIFFERENT
8	SPOT HERE. SO THE QUESTION THAT I WAS ASKING IS
9	WHETHER THE RETROACTIVITY CLAUSE APPLIED ANYWHERE IN
10	THE LIFE OF THE PROJECT, OR WHETHER IT WAS IN A
11	SENSE UP TO A POINT. SUPPOSE YOU'RE IN THE PROJECT
12	AND YOU'RE TWO YEARS INTO IT. DO YOU RECALIBRATE
13	ALL THE WAY BACK TO THE STARTING POINT OR FROM TWO
14	YEARS ON?
15	CHAIRMAN KLEIN: SO, DUANE, I THINK YOU
16	SHOULD ANSWER THE QUESTION. WHAT IS THE INTENT?
17	MR. ROTH: I THINK THE INTENT IS AS WE
18	MODIFY THESE PROGRAMS, WHICH WE'VE DONE MUCH THE WAY
19	WE DID WITH THE INTELLECTUAL PROPERTY PROCESS, THAT
20	CERTAINLY WE SHOULD NEGOTIATE IF WE MAKE A MATERIAL
21	CHANGE WITH THE PEOPLE THAT ARE ALREADY AFFECTED.
22	AND WE COULD DO TWO THINGS ON THAT. I THINK WE NEED
23	THE FLEXIBILITY, I GUESS, IS THE BOTTOM LINE. THE
24	FLEXIBILITY WOULD MEAN THAT WE WOULD GO BACK AND
25	READJUST FROM THE BEGINNING OF TIME, OR WE COULD DO

1	IT FROM THAT POINT FORWARD AND MAKE A DECISION WHAT
2	WAS THE MOST APPROPRIATE.
3	MS. BAUM: CAN I SUGGEST, THOUGH, THAT
4	CONSIDERATION BE TAKEN TO MAYBE EXCLUDE SITUATIONS
5	WHERE THERE'S ALREADY A LOAN AGREEMENT IN PLACE?
6	BECAUSE THEN YOU'D HAVE TO REVISE
7	MR. ROTH: REDO THE LOAN AGREEMENT.
8	CHAIRMAN KLEIN: WELL, ELONA, OUR CURRENT
9	LANGUAGE ACTUALLY ALLOWS, EVEN IF THERE'S A LOAN
10	AGREEMENT IN PLACE AND THE PRIOR THEORY, WE'LL ALL
11	RECALL, WAS WE DIDN'T WANT COMPANIES HOLDING BACK
12	FROM GRANT ROUNDS WAITING FOR TERMS TO CHANGE. AND
13	SO, DUANE, MAYBE A BALANCE THAT YOU COULD CONSIDER
14	AS A FRIENDLY AMENDMENT OR SOME OTHER OPTION THAT
15	SOMEONE ELSE MIGHT SUGGEST WOULD BE THAT TO THE
16	EXTENT THAT AN ADVANCE HAS OCCURRED AND THE WARRANTS
17	HAVE BEEN SET UNDER THAT ADVANCE, IT WOULD APPLY TO
18	FUTURE ADVANCES, BUT NOT TO THE ADVANCE UNDER WHICH
19	THE WARRANT FORMULA HAD ALREADY APPLIED. WHAT WOULD
20	YOU THINK OF THAT?
21	MR. ROTH: THAT WOULD BE FINE. I HADN'T
22	REALLY, TO PHIL'S QUESTION, HADN'T REALLY THOUGHT
23	THROUGH THAT, BUT I WANTED TO MAKE SURE THE
24	FLEXIBILITY WAS THERE, THAT IF WE NEED TO MAKE A
25	CHANGE, THAT WE HAVE THE OPPORTUNITY TO GO BACK AND
	14

ĺ	
1	ADJUST THAT. BUT I THINK THAT'S BUILT INTO THE
2	LANGUAGE THAT BOB FIRST ASKED JAMES OR ELONA TO
3	COMMENT ON.
4	CHAIRMAN KLEIN: OKAY.
5	MR. ROTH: I'M FINE WITH THAT.
6	CHAIRMAN KLEIN: ALL RIGHT.
7	CHAIRMAN GOLDBERG: SO DO WE NEED TO HAVE
8	FURTHER DISCUSSION ON THE WARRANT ALTERNATIVES,
9	SUBCOMMITTEE MEMBERS? IF NOT, DUANE, WOULD YOU LIKE
10	TO PROPOSE A MOTION?
11	CHAIRMAN KLEIN: DO WE HAVE A QUORUM?
12	CHAIRMAN GOLDBERG: WE DO.
13	MS. KING: JUST A QUICK CHECK, DR.
14	STEWARD, WERE YOU ABLE TO JOIN US?
15	DR. STEWARD: YES, I'M HERE. THANK YOU.
16	MS. KING: THANK YOU. I HEARD YOU JOIN US
17	REALLY AT THE BEGINNING OF THE PRESENTATION OF THIS
18	ITEM. YOU'RE AS UP TO SPEED AS EVERYBODY ELSE.
19	DR. STEWARD: OKAY. THANK YOU.
20	MR. ROTH: SO I WOULD MOVE THAT WE ACCEPT
21	THE PROPOSED LANGUAGE IN BOTH CASES, THE
22	COMPANY-BACKED AND THE PRODUCT-BACKED LOAN
23	AMENDMENT, AS PRESENTED.
24	DR. PIZZO: SECOND.
25	CHAIRMAN GOLDBERG: OKAY. CAN YOU CALL
	15

1	ROLL, PLEASE, MELISSA. OH, PUBLIC COMMENT. POLL
2	THE SITES.
3	MS. KING: NONE HERE IN SAN FRANCISCO.
4	REMIND ME. YOU DON'T HAVE ANY PUBLIC AT STANFORD,
5	CORRECT?
6	CHAIRMAN GOLDBERG: NO.
7	MS. KING: THAT'S NONE AT SAN FRANCISCO
8	AIRPORT. KLEIN FINANCIAL IS NOT ON THE PHONE.
9	DR. STEWARD, DO YOU HAVE ANY MEMBERS OF THE PUBLIC
10	WITH YOU?
11	DR. STEWARD: NO PUBLIC HERE.
12	MS. KING: OKAY. AND, MR. ROTH, YOU DON'T
13	HAVE ANY MEMBERS OF THE PUBLIC, DO YOU?
14	MR. ROTH: NO.
15	MS. KING: NONE AT UC BERKELEY, IF I
16	RECALL, DR. PRICE.
17	DR. PRICE: CORRECT.
18	MS. KING: I DON'T BELIEVE DR. PENHOET HAS
19	JOINED US, BUT I WOULD LIKE TO KNOW. NO. OKAY.
20	AND, DR. LOVE, YOU DON'T HAVE ANY MEMBERS OF THE
21	PUBLIC WITH YOU, CORRECT?
22	DR. LOVE: NO.
23	MS. KING: OKAY. AND IT LOOKS LIKE THERE
24	ARE NO PUBLIC COMMENTS HERE IN SAN FRANCISCO; IS
25	THAT CORRECT? OKAY.

1		CHAIRMAN GOLDBERG: TAKE THE ROLL CALL,
2	PLEASE, M	ELISSA.
3		MS. KING: ROBERT PRICE.
4		DR. PRICE: YES.
5		MS. KING: MICHAEL GOLDBERG.
6		CHAIRMAN GOLDBERG: YES.
7		MS. KING: BOB KLEIN.
8		CHAIRMAN KLEIN: YES.
9		MS. KING: TED LOVE.
10		DR. LOVE: YES.
11		MS. KING: PHIL PIZZO.
12		DR. PIZZO: YES.
13		MS. KING: DUANE ROTH.
14		MR. ROTH: YES.
15		MS. KING: DAVID SERRANO-SEWELL.
16		MR. SERRANO-SEWELL: YES.
17		MS. KING: JEFF SHEEHY.
18		MR. SHEEHY: YES.
19		MS. KING: OSWALD STEWARD.
20		DR. STEWARD: YES.
21		MS. KING: AND ART TORRES.
22		MR. TORRES: YES.
23		MS. KING: AND FOR THE RECORD THAT MOTION
24	CARRIES.	
25		CHAIRMAN GOLDBERG: THANK YOU.
		17
		1 /

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. KING: TEN YES VOTES.
2	CHAIRMAN GOLDBERG: I'D LIKE TO ASK BOB
3	KLEIN TO DISCUSS THE ITEM B IN THE ITEM 3 MEMO
4	CONCERNING THE PAYBACK ALTERNATIVES, AND THEN WE'LL
5	COMMENCE WITH FULL DISCUSSION OF THAT.
6	CHAIRMAN KLEIN: SO AS BACKGROUND ON THIS
7	AMENDMENT, I ACTUALLY BELIEVE THAT IN THE LONG RUN,
8	THAT THE PROGRAM THAT DUANE JUST REFINED IS
9	GOING MAKES A LOT OF SENSE INTELLECTUALLY. THE
10	REASON AND I HAVE BEEN A BIG SUPPORTER OF
11	WARRANTS. I HAVE GONE THROUGH, WITH TED LOVE'S
12	HELP, TALKED TO PAUL CLEVELAND, THE CFO OF
13	AFFYMETRIX, I'VE TALKED TO DAN SIEGELMAN, I'VE MET
14	WITH STEM CELLS, INC., I'VE TALKED TO NOVOCELL, I'VE
15	TALKED TO INDIVIDUALS FROM IPERIAN TRYING TO GET A
16	SENSE, ALONG WITH PROBABLY A DOZEN OTHER COMPANIES,
17	AND THERE WAS PROBABLY NINE COMPANIES IN A BAYBIO
18	DINNER IN MENLO PARK WHERE THIS WAS THE SUBJECT OF
19	DISCUSSION.
20	THE KEY HERE IS THAT OUR PRIMARY
21	OBLIGATION IS TO GET SOMETHING THAT WORKS FOR
22	BIOMEDICAL RESEARCH AND WORKS FOR COMPANIES AS WELL.
23	WE NEED COMPANIES IN AS PARTNERS. AND
24	INTELLECTUALLY, WHILE I BELIEVE THAT WE MAY
25	EVENTUALLY HAVE ENOUGH VOLUME AND ENOUGH OF A
	10

1	REPUTATION AND BE ABLE TO GET THROUGH TO ENOUGH
2	INVESTORS AND BOARD MEMBERS THAT WE CAN CONVINCE
3	THEM THAT THE WARRANT PROGRAM WORKS, FOR COMPANIES
4	IT MAY WORK AND FOR OTHER COMPANIES THEY JUST
5	ABSOLUTELY HAVE NOT BEEN WILLING TO SUBMIT
6	APPLICATIONS.
7	STEM CELLS, INC. IS THE EXAMPLE THAT I
8	KNOW THE BEST. I'VE MET WITH THEM FOUR TIMES, AND
9	THEY CANNOT THE HAVE DIVISIONS OF OPINION WITHIN
10	THEIR OWN COMPANY. THEY CANNOT GET THEIR COMPANY TO
11	AGREE EVEN ON BATTEN'S DISEASE.
12	SO THE ISSUE HERE IS THAT WE HAVE A
13	LIMITED TIME MANDATE. TIME IS NOT ON OUR SIDE FOR
14	PATIENTS. EVERY DAY LOST IS PART OF THEIR LIFE
15	THAT'S LOST. AND TRYING TO GET ANOTHER OPTION FOR
16	COMPANIES THAT MAY BRING MORE IN, TRYING TO GET
17	ANOTHER OPTION HAVING IT FOR A LIMITED TIME PERIOD,
18	AND I'M PRINCIPALLY FOCUSED RIGHT NOW ON THE NEW
19	DISEASE TEAM ROUND BECAUSE IN THE NEW DISEASE TEAM
20	ROUNDS, THE REQUEST FOR THE PLANNING GRANTS, WHICH
21	IS THE GATEWAY CURRENTLY FOR ENTRY INTO THAT ROUND,
22	START IMMEDIATELY, AND IT'S A TWO YEAR-ROUND. SO WE
23	CAN'T AFFORD TO LOSE THAT ROUND FOR COMPANIES.
24	SO IN THAT CONTEXT AND HISTORICAL FRAME,
25	GIVEN THE PRIORITY OF OUR OBLIGATION TO FIRST GET

1	THERAPIES TO PATIENTS, I'VE APPROVED I HAVE
2	PROPOSED THIS OPTION. IT'S PROPOSED WITH A TWO-YEAR
3	END PERIOD FOR REEVALUATION; BUT, IN FACT, IF WE
4	FIND THAT WE'RE ABLE TO CONTINUE TO REFINE THE
5	WARRANT SIDE AND WE'RE GETTING ACCEPTANCE, WE COULD
6	END THIS OPTION MUCH EARLIER. WE COULD END IT IN
7	SIX MONTHS.
8	THE KEY HERE IS TO GET SOME MOMENTUM AND
9	GET PARTICIPATION BECAUSE PARTICIPATION OF COMPANIES
10	ENHANCES OUR ABILITY TO GET TO THERAPIES. AND SO IF
11	COMPANIES SEE THIS AS A BETTER DEAL IN THE NEXT SIX
12	MONTHS AND WE GET SOME THERAPIES OUT OF IT, I THINK
13	PATIENTS AND THE TAXPAYERS OF CALIFORNIA ARE THE
14	WINNERS BECAUSE THESE PAYBACKS IS NOT WHAT WE'RE ALL
15	ABOUT. THESE ARE AN ENHANCEMENT TO OUR MISSION, NOT
16	OUR PRIMARY MISSION.
17	SO WITH THAT CONTEXT, UNDERSTANDING THAT I
18	REALLY SUPPORT LONG TERM THE PROPOSAL THAT DUANE IS
19	CONTINUING TO REFINE, JAMES OR LYNN, COULD YOU GO
20	THROUGH THE OPTIONS UNDER THIS ALTERNATIVE?
21	CHAIRMAN GOLDBERG: ON ATTACHMENT A.
22	MR. HARRISON: SURE. THERE WAS WITH THE
23	WARRANT COVERAGE A DIVISION FOR PRODUCT-BACKED LOANS
24	AND COMPANY-BACKED LOANS, AND IT'S, I THINK, PRETTY
25	CLEARLY SET FORTH IN ATTACHMENT A. THERE ARE THREE

1	DIFFERENT TRIGGERS: \$10 MILLION IN ANNUAL REVENUES,
2	300 MILLION IN CUMULATIVE REVENUES, AND THE THIRD
3	TRIGGER IS 600 MILLION IN CUMULATIVE REVENUES. AND
4	YOU WILL SEE, THE PAYBACK PREMIUM VARIES DEPENDING
5	UPON WHETHER IT'S A PRODUCT-BACKED LOAN OR A
6	COMPANY-BACKED LOAN AND ALSO DEPENDING UPON WHICH
7	TRIGGER IS MET.
8	SO, FOR EXAMPLE, FOR A PRODUCT-BACKED
9	LOAN, WHEN THE FIRST TRIGGER IS MET, THE PAYBACK
10	RISK PREMIUM WOULD BE 100 PERCENT OF THE ORIGINAL
11	LOAN AMOUNT AND INTEREST. FOR A COMPANY-BACKED LOAN
12	WHEN THE FIRST TRIGGER IS MET, THERE WOULD BE NO
13	PREMIUM DUE. AND THEN, AS YOU WILL SEE ON THE
14	CHART, IT ESCALATES AS THE COMPANY ACHIEVES GREATER
15	AND GREATER SUCCESS.
16	CHAIRMAN KLEIN: AND, AGAIN, IF THE
17	COMMITTEE AND THE BOARD FELT THAT AFTER HAVING A
18	SPECIFIC EFFORT IN THE NEXT SIX MONTHS TO COLLECT
19	INFORMATION AND TRY AND REFINE THE OTHER OPTION THAT
20	DUANE JUST PRESENTED, THAT THIS OPTION WAS NO LONGER
21	NECESSARY, THEN I THINK IT'S PERFECTLY APPROPRIATE
22	TO COME BACK AND ELIMINATE THIS OPTION. SO THIS IS
23	TO TRY AND GET AN OPTION ON THE BOARD IMMEDIATELY
24	EFFECTIVE FOR THIS DISEASE TEAM ROUND, BUT I THINK
25	WE NEED TO CONTINUE TO FOLLOW UP BECAUSE EVENTUALLY

1	MY HOPE IS THAT THE FIRST PROGRAM THAT DUANE HAD
2	DISCUSSED WITH REFINEMENTS THAT HE'S CURRENTLY
3	MAKING, THAT WOULD BE THE LONG-TERM OPTION THAT
4	MIGHT BE THE BEST OPTION. BUT THIS GIVES US AN
5	ABILITY, PARTICULARLY FOR THE DISEASE TEAM ROUNDS,
6	THE PLANNING GRANT AND THE FINAL ROUND, TO HAVE MORE
7	COMPANY PARTICIPATION.
8	SO, MR. CHAIRMAN, I HAVE NOT HEARD
9	IPERIAN'S DISCUSSION OF THIS OPTION SINCE IT WAS
10	ORIGINALLY PROPOSED. THEY MADE A COMMENT IN THE
11	LAST PUBLIC SESSION OF THE FINANCE COMMITTEE. CAN
12	WE SEE WHAT THEIR VIEW IS ON THIS AND SEE WHETHER
13	WE'VE GOT IT REFINED ENOUGH OR WE DON'T.
14	CHAIRMAN GOLDBERG: FIRST, LET ME ASK IF
15	WE CAN GO AROUND THE COMMITTEE FOR ANY CLARIFYING
16	QUESTIONS.
17	MS. BAUM: I DON'T HAVE A QUESTION, BUT
18	MR. KLEIN HAD ASKED ME TO PROVIDE SOME INFORMATION
19	WHICH I NOW HAVE AVAILABLE.
20	CHAIRMAN KLEIN: ALL RIGHT.
21	MS. BAUM: SO I WANTED TO MAKE THAT
22	AVAILABLE. SO I WANTED TO LET THE COMMITTEE KNOW
23	THAT SANGAMO'S CEO HAD SAID IN THE PAST, AND HE'S
24	HAPPY TO SHARE THAT TODAY, THAT THEY WOULD NOT BE IN
25	A POSITION TO TAKE A LOAN WITH WARRANTS. SO I

1	NEEDED TO CONVEY THAT.
2	MR. ROTH: I HAVE TO MICHAEL, I'M GOING
3	TO ASK YOU TO
4	CHAIRMAN GOLDBERG: GO AHEAD, DUANE.
5	MR. ROTH: SO THE QUESTION I HAVE FOR YOU
6	IS IS THIS REALLY YOUR EXPERIENCE AS A VENTURE
7	CAPITALIST WITH A PORTFOLIO, THAT YOUR PORTFOLIO
8	COMPANIES NO LONGER GRANT WARRANTS?
9	CHAIRMAN GOLDBERG: NO, THAT'S NOT BEEN MY
10	EXPERIENCE. MY EXPERIENCE IS THAT COMPANIES GRANT
11	WARRANTS UNDER CIRCUMSTANCES THAT REQUIRE THEM.
12	MR. ROTH: SO THAT'S WHY I'M NOT
13	SUGGESTING HERE THAT WE DON'T LOOK AT THIS
14	EMPIRICALLY AND FIND OUT IF WE'RE RIGHT OR WRONG.
15	BUT I THINK WE SHOULD DO THE WORK BEFORE WE RUSH
16	INTO MAKING A CHANGE. I'M SENSITIVE TO THE NEED,
17	AND I WANT COMPANIES TO APPLY. PERSONALLY I DON'T
18	THINK IT'S THE WARRANTS THAT ARE THE PROBLEM. BUT I
19	COULD BE WRONG; AND IF I AM, I WOULD BE HAPPY TO
20	HAVE MORE DIALOGUE ON THAT.
21	I KNOW THAT COMPANIES DISLIKE GIVING
22	WARRANTS; AND ESPECIALLY THEIR BOARDS, AND
23	PARTICULARLY IF THEIR BOARDS HAVE VENTURE CAPITAL
24	INVOLVED, THEY REALLY LIKE TO KEEP ALL THE EQUITY
25	FOR THEMSELVES. BUT EVEN IN THE COMPANIES THAT YOU

1	MENTIONED, BOB, I'D LIKE TO KNOW IF THEY HAVE ANY
2	WARRANTS ISSUED.
3	CHAIRMAN KLEIN: SO, DUANE, THE ISSUE FOR
4	ME IS AND I CLEARLY KNOW THAT COMPANIES ARE
5	GIVING WARRANTS. THE DIFFERENCE WE HAVE HERE, WHICH
6	IS VERY SUBSTANTIAL ACCORDING TO THE COMPANIES, IS
7	THAT WHEN THEY HAVE AN EARLY INVESTOR IN THE
8	COMPANY, THEY DECIDE WHO THEIR INVESTOR IS. THEY
9	HAVE PAST RELATIONSHIPS WITH THESE PEOPLE. THEY
10	KNOW HOW THEY'RE GOING TO ACT. THEY CAN HAVE
11	CONSTRAINTS ON WHERE THOSE WARRANTS CAN BE SOLD.
12	MR. ROTH: I UNDERSTAND, BOB, ALL THAT.
13	THAT'S A COMPLETELY DIFFERENT STORY THOUGH.
14	CHAIRMAN KLEIN: HOLD ON. THE PROBLEM IS
15	THAT THESE WARRANTS WITH US, THEY HAVE NO CONTROL
16	OVER HOW WE SELL THESE WARRANTS, WHO WE SELL THEM
17	TO. THEY COULD HAVE HOSTILE PARTIES BUY THE
18	WARRANTS.
19	MR. ROTH: I UNDERSTAND ALL THAT. I'VE
20	HEARD THAT STORY AT MEETINGS PREVIOUSLY. THAT WE
21	CAN ADDRESS. IF YOU WANT TO ADDRESS THAT, WE CAN DO
22	IT IN THE WARRANT AGREEMENT.
23	CHAIRMAN KLEIN: ALL RIGHT. THAT'S
24	PERFECTLY ACCEPTABLE. THE PROBLEM IS UNDER OUR
25	REGULATORY PROCESS, GIVEN THAT THIS PROGRAM HAS
	24

1	ALREADY GONE THROUGH THE ADMINISTRATIVE PROCEDURES
2	ACT, IT'S MY UNDERSTANDING IT WOULD TAKE US ABOUT
3	FOUR OR FIVE MONTHS TO ADDRESS THAT, WHICH MEANS
4	THAT WE COMPLETELY MISS THE IMMINENT DISEASE TEAM
5	ROUND, WHICH IS WHY I'M REFERRING TO THE FACT THAT
6	IF WE COME BACK FOUR OR FIVE MONTHS LATER AND HAVE
7	THESE OTHER MODIFICATIONS IN PLACE UNTIL WE CAN
8	ELIMINATE THIS PROGRAM, FINE. I'M JUST TRYING TO
9	GET COMPANY PARTICIPATION WITH AN AVENUE FOR THIS
10	PARTICULAR DISEASE TEAM ROUND WHICH IS SO IMPORTANT
11	TO US.
12	MR. ROTH: OKAY. THEN I HAVE A
13	SUGGESTION. WHY DON'T WE JUST PUT THEM ALL THEY
14	CAN EITHER TAKE A LOAN OR A GRANT.
15	CHAIRMAN KLEIN: WELL, SO THAT'S NOT MY
16	PROPOSAL.
17	MR. ROTH: I UNDERSTAND, BUT WHY NOT?
18	JUST LET'S MAKE THEM ALL GRANTS.
19	CHAIRMAN KLEIN: OKAY. WELL, I RESPECT
20	THAT ALTERNATIVE. BUT I THINK THAT THE LOAN PROGRAM
21	YOU JUST MODIFIED IS A VERY GOOD PROGRAM LONG-TERM.
22	I'M TRYING TO CREATE AN IMMEDIATE OPTION TO CREATE
23	VIABILITY FOR THE BROADEST POSSIBLE PARTICIPATION BY
24	COMPANIES IN THIS DISEASE TEAM ROUND AND THE ROUNDS
25	THAT WILL OCCUR BEFORE THE FIVE-MONTH PROCESS IT

1	WOULD TAKE US TO MAKE THE MODIFICATION WE JUST
2	ADDRESSED.
3	CHAIRMAN GOLDBERG: IS THERE ANY OTHER
4	QUESTIONS FROM MEMBERS OF THE COMMITTEE?
5	MR. SHEEHY: I HAVE TO SAY I AGREE WITH
6	DUANE. I MEAN THIS YOU KNOW, I DON'T REALLY KNOW
7	ABOUT IT SEEMS TO ME THAT IF I WERE A COMPANY, I
8	WOULD GO FOR THIS OPTION AND WE WOULDN'T GET ANY
9	WARRANTS. YOU KNOW, SEEMS LIKE A REALLY QUICK AND
10	EASY WAY TO DO THIS IS JUST TO OFFER COMPANIES THE
11	OPTION OF TAKING A GRANT, WHICH GIVES YOU THE SAME
12	TERMS VIRTUALLY, YOU KNOW, AND KIND OF ALLEVIATES
13	THIS CONCERN. OTHERWISE, WE KIND OF ANNIHILATE OUR
14	WARRANT PROGRAM, WHICH, YOU KNOW, IF THAT'S WHAT WE
15	WANT TO DO, BUT LET'S BE CLEAR ABOUT WHAT WE'RE
16	TRYING TO DO HERE. IF WE WANT TO HAVE A WARRANT
17	PROGRAM, WE SHOULD PROBABLY DECIDE
18	CHAIRMAN GOLDBERG: I THINK THERE'S
19	ANOTHER APPROACH, WHICH IS PERHAPS A SLIGHT
20	MODIFICATION OF WHAT'S BEEN ARTICULATED ABOUT THE
21	PAYBACK OPTION, WHICH IS PUT A VERY SPECIFIC SUNSET
22	PROVISION ON IT. LET'S CALL IT ONE YEAR. AND THAT,
23	YOU KNOW, IT'S AN EXPERIMENT. THIS IS A WORK IN
24	PROGRESS JUST LIKE THE INTELLECTUAL PROPERTY
25	GUIDELINES WERE A WORK IN PROGRESS. AND WE SEE WHAT
	26
25	

1	HAPPENS BEFORE WE DEFAULT TO JUST A GRANT WHERE
2	THERE'S NO RISK PREMIUM THAT COMES BACK TO THE STATE
3	TO FUND CONTINUED TRANSLATIONAL RESEARCH.
4	MR. ROTH: WELL, THE RISK PREMIUM DOES
5	COME BACK, MICHAEL. IT GOES TO THE STATE, NOT TO
6	CIRM. THIS WOULD COME BACK THE PROPOSAL THAT IS
7	ON THE TABLE WOULD COME BACK TO THE AGENCY. YOU
8	KNOW, THIS IS ONE OF THE THINGS WE DISCUSSED WITH
9	THE LEGISLATORS ON THE DIFFERENCE BETWEEN WARRANTS
10	AND THAT COMING BACK AND LOAN REPAYMENTS COMING BACK
11	VERSUS ROYALTIES.
12	CHAIRMAN KLEIN: I SPECIFICALLY WROTE THE
13	INITIATIVE FOR A LOAN REPAYMENT AND RISK PREMIUMS ON
14	THOSE TO COME BACK TO OUR AGENCY.
15	I'D LIKE TO MAKE A MOTION AND SEE IF WE
16	HAVE THE VOTES OR WE DON'T AND WITH PUBLIC COMMENT.
17	AND THAT MOTION IS TO ADOPT THE THIS OPTION FOR
18	COMPANIES FOR A ONE-YEAR PERIOD. AND DURING THAT
19	TIME TO TRY AND REFINE THE OTHER PROGRAM TO DEAL
20	WITH THE ISSUES COMPANIES HAVE WITH OUTSIDE LEGAL
21	SUPPORT; AND INSTEAD OF THE TWO-YEAR PERIOD WHICH I
22	HAD, I'M ACCEPTING THE CHAIRMAN'S ONE-YEAR PERIOD IF
23	THE CHAIRMAN WOULD MAKE THAT A SECOND.
24	CHAIRMAN GOLDBERG: I'M PREPARED TO SECOND
25	THAT MOTION. IS THERE PUBLIC COMMENT? COULD YOU

1	POLL THE SITES, MELISSA.
2	DR. PIZZO: JUST POLL THE SITES THAT HAVE
3	PUBLIC.
4	MS. KING: SURE. I'LL POLL THE SITES. WE
5	DON'T HAVE ANY HERE IN SAN FRANCISCO. THERE WAS NO
6	PUBLIC AT STANFORD, NO PUBLIC AT THE SAN FRANCISCO
7	AIRPORT, NO JOINING PARTIES FROM KLEIN FINANCIAL, NO
8	PUBLIC AT IRVINE, NO PUBLIC AT CONNECT, NO PUBLIC AT
9	BERKELEY. ALTA PARTNERS, IS ED PENHOET ON THE LINE?
10	I THOUGHT MAYBE ED HAD JOINED. DOESN'T SOUND LIKE
11	IT. NO PUBLIC AT ONYX. SO THERE'S NO PUBLIC
12	COMMENTS.
13	CHAIRMAN GOLDBERG: OKAY. SO COULD YOU
14	CALL THE COMMITTEE WITH RESPECT TO THE MOTION ON THE
15	TABLE?
16	MS. KING: SO TAKING A ROLL CALL VOTE, DR.
17	ROBERT PRICE.
18	DR. PRICE: YES.
19	MS. KING: MICHAEL GOLDBERG.
20	CHAIRMAN. GOLDBERG: YES.
21	MS. KING: BOB KLEIN.
22	CHAIRMAN KLEIN: YES.
23	MS. KING: TED LOVE.
24	DR. LOVE: YES.
25	MS. KING: PHIL PIZZO.
	28
	20

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	
1	DR. PIZZO: YES.
2	MS. KING: DUANE ROTH.
3	MR. ROTH: NO.
4	MS. KING: DAVID SERRANO-SEWELL.
5	MR. SERRANO-SEWELL: YES.
6	MS. KING: JEFF SHEEHY.
7	MR. SHEEHY: NO.
8	MS. KING: OSWALD STEWARD.
9	DR. STEWARD: NO.
10	MS. KING: AND ART TORRES.
11	MR. TORRES: AYE.
12	MS. KING: THANK YOU. JAMES, I'LL DEFER
13	TO YOU FOR WHETHER OR NOT THE MOTION CARRIES.
14	MR. HARRISON: YES. THE MOTION CARRIES
15	WITH SEVEN YES VOTES AND THREE NO VOTES.
16	CHAIRMAN GOLDBERG: OKAY. THANK YOU. I'D
17	LIKE TO IN THE TIME THAT REMAINS BRIEFLY ADDRESS THE
18	CLIMATE FOR CALIFORNIA BOND ISSUANCE SINCE WE'RE
19	GOING AS AN AGENCY DEPENDENT ON THEIR BOND
20	AUTHORITY. AND THERE'S BEEN ARTICLES IN THE PRESS
21	IN THE LAST TWO WEEKS IN CONNECTION WITH THE LAST
22	LARGE SERIES OF BOND FINANCINGS THE STATE HAS DONE
23	ABOUT SOME OF THE CHALLENGES AND DIFFICULTIES. AND
24	WITHOUT GETTING INTO ANY OF THE SPECIFICS OF THOSE
25	ISSUES, I'D LIKE TO ASK CHAIRMAN KLEIN, WHO'S
	29

1	MAINTAINED CONTACT WITH THE ISSUING AUTHORITIES,
2	WHAT THE GENERAL PERSPECTIVE OR VIEW IS OVER THE
3	COURSE OF THE NEXT 12 TO 24 MONTHS AND WHETHER OR
4	NOT THERE'S ANY CAUSE FOR ACTION ON THE PART OF THE
5	ICOC WITH RESPECT TO ANYTHING WE CAN OR SHOULD BE
6	DOING BEING MINDFUL OF THAT.
7	CHAIRMAN KLEIN: THANK YOU, CHAIRMAN
8	GOLDBERG. SO GIVEN THAT OVER THE LAST THREE YEARS
9	WE'VE TRIED TO ALWAYS LOOK FORWARD AT LEAST A COUPLE
10	OF YEARS AND FOR SEEING THE DIFFICULT ENVIRONMENT
11	PARTICULARLY WITH SOME OF THE INITIATIVES THAT
12	PASSED IN THIS LAST SESSION, THIS LAST ELECTORAL
13	CYCLE, WE'VE BEEN FORTUNATE, BY DOING ADVANCED
14	PLANNING, TO MAKE SURE WE COULD COVER OUR STRATEGIC
15	PLAN ADVANCES WE WOULD NEED TO MAKE OVER THE RUNNING
16	24-MONTH PERIOD GOING FORWARD.
17	AT THIS POINT WE'VE ACHIEVED THAT
18	OBJECTIVE, AND WE HAVE A LITTLE LESS THAN 24 MONTHS,
19	BUT APPROXIMATELY THAT LEVEL OF CASH FUNDING THAT'S
20	AVAILABLE TO US. SO OUR PROGRAMS ARE VERY STABLE
21	DURING THIS PERIOD. IT'S HOPEFUL THAT IN THAT TIME
22	PERIOD CALIFORNIA WILL RETURN TO A MUCH STRONGER
23	BOND POSITION.
24	NEVERTHELESS, FOR OUR SCIENTIFIC PARTNERS
25	AND OUR INTERNATIONAL PARTNERS AND OUR INDIVIDUAL

1	SCIENTISTS WITHIN THE STATE, IT'S IMPORTANT TO AGAIN
2	REMIND EVERYONE THAT UNDER THE STATE INSTITUTION,
3	THE TOP 40 PERCENT OF THE REVENUE OF THE STATE GOES
4	TO EDUCATION, AND THEN BOND DEBT SERVICE IS THE NEXT
5	PRIORITY AHEAD OF HARBORS, AHEAD OF MAJOR NEW
6	HIGHWAY CONSTRUCTION, AND OTHER PROJECTS TO THE
7	EXTENT THEY COME OUT OF STATE FUNDS VERSUS FEDERAL
8	FUNDS. SO CALIFORNIA WILL RETAIN THE ABILITY, EVEN
9	IF THIS DIFFICULT PERIOD IS A FULL TWO YEARS OR
10	LONGER, TO FUND THIS AGENCY ON A TIMELY BASIS. AND
11	INSTITUTIONS AND THE SCIENTISTS WILL BE COVERED IN
12	THE TIME PERIOD OF OUR COMMITMENT.
13	SO WE'RE VERY THANKFUL FOR THE SUPPORT OF
14	THE STATE TREASURER'S OFFICE AND FOR THE SUPPORT OF
15	THE GOVERNOR AND THE DIRECTOR OF FINANCE, FOR THE
16	WORK OF LYNN HARWELL, WHO HAS BEEN INSTRUMENTAL IN
17	EXECUTING ON THIS PLAN, FOR TED LOVE AND MARCY FEIT,
18	WHO HAVE BEEN ON THE BOND FINANCE CREDIT COMMITTEE
19	OF THE STATE WITH ME. AND WE ARE THANKFUL AND VERY
20	APPRECIATIVE OF THE FACT THAT WE'LL BE ABLE TO HONOR
21	OUR STRATEGIC PLAN AND HAVE THE FLEXIBILITY DURING
22	THAT TIME TO USE RESERVES THAT ARE SET UP
23	SPECIFICALLY TO RESPOND TO NEW SCIENTIFIC
24	DEVELOPMENTS THAT ARE CERTAINLY EXPECTED TO ARISE AT
25	VARIOUS TIMES DURING THAT CYCLE.

1	CHAIRMAN GOLDBERG: THANK YOU, CHAIRMAN
2	KLEIN. ARE THERE ANY COMMENTS OR QUESTIONS FROM THE
3	COMMITTEE?
4	CHAIRMAN KLEIN: I'D JUST LIKE TO SAY THAT
5	SENATOR TORRES IS INSTRUMENTAL IN OUR COMMUNICATIONS
6	WITH THAT COMMITTEE AND THE STATE TREASURER.
7	SENATOR TORRES, ARE YOU THERE?
8	MR. TORRES: YES.
9	CHAIRMAN KLEIN: I'D JUST LIKE TO THANK
10	YOU VERY MUCH FOR THAT CONSTANT CONTRIBUTION.
11	MR. TORRES: IT'S CALLED TEAM EFFORT, AND
12	THERE IS A TEAM AND WE WORKED TOGETHER AND THAT'S
13	WHAT MAKES IT WORK. THANK GOD THAT 47 MILLION CAME
14	IN.
15	CHAIRMAN KLEIN: HE'S REFERRING
16	SPECIFICALLY OUT OF THE LAST BOND ISSUE THAT JUST
17	OCCURRED WE OBTAINED ANOTHER 47 MILLION.
18	DR. PIZZO: GREAT.
19	CHAIRMAN KLEIN: THANK YOU VERY MUCH,
20	SENATOR.
21	MR. TORRES: THANK YOU, BOB.
22	CHAIRMAN GOLDBERG: ARE THERE ANY
23	COMMENTS FROM ANY OF THE SITES FROM THE PUBLIC?
24	MS. KING: THE ONE SITE WHERE THERE
25	MEMBERS OF THE PUBLIC IS SAN FRANCISCO, AND IT DOES
	22

32

1	NOT LOOK LIKE THERE ARE PUBLIC COMMENTS HERE. AM I
2	RIGHT, GENTLEMAN? THANK YOU.
3	CHAIRMAN GOLDBERG: THAT CONCLUDES THE
4	BUSINESS ON THE AGENDA. UNLESS THERE ARE ANY
5	OBJECTIONS FROM MEMBERS OF THE COMMITTEE, I'D LIKE
6	TO MOVE ADJOURNMENT.
7	(THE MEETING WAS THEN CONCLUDED.)
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	33

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE FINANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON FRIDAY, DECEMBER 3, 2010, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100